AB1029 Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART) study: baseline characteristics of the randomised patient population

Background

Allopurinol is licensed for the prevention of gout. In recent years, several studies have suggested that allopurinol may have beneficial effects on cardiovascular parameters. The ALL-HEART study is a large outcome trial designed to investigate whether allopurinol improves cardiovascular outcomes in patients with ischaemic heart disease[.¹ It is a multicentre, controlled, prospective, randomised, open-label, blinded...